Epidemiology, Health Care Resource Utilization, and Costs of Hemophilia A and B by Treatment Regimen: A Retrospective Analysis of German Claims Data from 2016 to 2021

Abstract

Introduction

In Germany, hemophilia patients with a severe bleeding phenotype receive lifelong prophylactic treatment with intravenous concentrated factor VIII (FVIII) or IX (FIX) to prevent bleeding events. To assess the economic value of emerging treatment options, studies describing the economic burden of hemophilia under the current standard of care in Germany are needed.

Aim

This study classified hemophilia A (HA) and B (HB) patients by treatment regimen in administrative claims data to examine the real-world economic burden of Hemophilia in Germany from 2016 to 2021.

Methods

Hemophilia patients were identified in InGef statutory health insurance claims data via ICD-10 codes D66 (HA) and D67 (HB) in combination with one or more claims for hemophilia-related medication.

Each patient's factor regimen was classified as either indicative of a severe phenotype needing prophylaxis or a non-severe phenotype treated on demand using a classification threshold of 100,000 International Units (IU) FVIII/year (HA) and 80,000 IU FIX/year (HB). Health care resource utilization and cost outcomes were captured for each study year.

Results

Male prevalence per 100,000 ranged from 6.39 to 7.81 (HA) and 1.26 to 1.89 (HB), with 43 to 53% (HA) and 40 to 56% (HB) categorized as severe. In 2021, mean (standard deviation [SD]) per-patient medication costs were €321,987 (€157,915) in the severe treatment group versus €43,487 (€92,821) in the non-severe group for HA and €289,411 (€132,400) versus €19,253 (€23,655) for HB.

Conclusion

The results demonstrate the high economic burden of severe HA and HB in Germany, driven by the need for continuous factor replacement therapy, and give an estimate of treatment costs based on a real-world therapy mix.

Keywords

hemophilia A - hemophilia B - health care resource utilization - healthcare costs - Germany

• References

• 1 Deutsches Hämophilieregister. Jahresbericht 2021. 2021
• 2 Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 2010; 16 (01) 20-32
• 3 Stonebraker JS, Bolton-Maggs PH, Michael Soucie J, Walker I, Brooker M. A study of variations in the reported haemophilia B prevalence around the world. Haemophilia 2012; 18 (03) e91-e94
• 4 Alam AU, Karkhaneh M, Attia T, Wu C, Sun HL. All-cause mortality and causes of death in persons with haemophilia: A systematic review and meta-analysis. Haemophilia 2021; 27 (06) 897-910
• 5 Iorio A, Stonebraker JS, Chambost H. et al.; Data and Demographics Committee of the World Federation of Hemophilia. Establishing the prevalence and prevalence at birth of hemophilia in males: A meta-analytic approach using national registries. Ann Intern Med 2019; 171 (08) 540-546
• 6 Bundesärztekammer. Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. 2020
• 7 Okaygoun D, Oliveira DD, Soman S, Williams R. Advances in the management of haemophilia: emerging treatments and their mechanisms. J Biomed Sci 2021; 28 (01) 64
• 8 Buckner TW, Bocharova I, Hagan K. et al. Health care resource utilization and cost burden of hemophilia B in the United States. Blood Adv 2021; 5 (07) 1954-1962
• 9 Burke T, Asghar S, O'Hara J, Chuang M, Sawyer EK, Li N. Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe. Orphanet J Rare Dis 2021; 16 (01) 521
• 10 Cavazza M, Kodra Y, Armeni P. ,et al.; BURQOL-RD Research Network. Social/economic costs and quality of life in patients with haemophilia in Europe. Eur J Health Econ 2016; 17 (Suppl. 01) 53-65
• 11 Chen SL. Economic costs of hemophilia and the impact of prophylactic treatment on patient management. Am J Manag Care 2016; 22 (05) s126-s133
• 12 O'Hara J, Hughes D, Camp C, Burke T, Carroll L, Diego DG. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis 2017; 12 (01) 106
• 13 Rodriguez-Santana I, DasMahapatra P, Burke T. et al. Differential humanistic and economic burden of mild, moderate and severe haemophilia in european adults: a regression analysis of the CHESS II study. Orphanet J Rare Dis 2022; 17 (01) 148
• 14 Zhou ZY, Koerper MA, Johnson KA. et al. Burden of illness: direct and indirect costs among persons with hemophilia A in the United States. J Med Econ 2015; 18 (06) 457-465
• 15 Ludwig M, Enders D, Basedow F, Walker J, Jacob J. Sampling strategy, characteristics and representativeness of the InGef research database. Public Health 2022; 206: 57-62
• 16 Caplan EO, Patel AM, DeClue RW. et al. Real-world treatment, clinical outcomes and healthcare resource utilization among persons with hemophilia A by age. J Comp Eff Res 2021; 10 (15) 1121-1131
• 17 Srivastava A, Santagostino E, Dougall A. ,et al.; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 (Suppl. 06) 1-158
• 18 Neuhauser H. Referenzperzentile für anthropometrische Maßzahlen und Blutdruck aus der Studie zur Gesundheit von Kindern und Jugendlichen in Deutschland (KiGGS). 2013
• 19 Statistisches Bundesamt. Bevölkerung: Deutschland, Stichtag, Altersjahre [Internet]. 2023 . Accessed April 10, 2025 at: https://www-genesis.destatis.de/genesis//online?operation=table&code=12411-0005&bypass=true&levelindex=1&levelid=1694766358002#abreadcrumb
• 20 Deutsches Hämophilieregister. Jahresbericht 2020. 2020
• 21 Berntorp E, Fischer K, Hart DP. et al. Haemophilia. Nat Rev Dis Primers 2021; 7 (01) 45
• 22 Schmitt N. Gentherapie der Hämophilie – Medizinisch-ökonomische Analyse der AMNOG-Preisverhandlungen. 2023